Bruton Tyrosine Kinase Inhibitors (BTK inhibitors)
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.590 alerts
Get alerted when Policy 5.01.590 changes without checking for updates manually.
Monitor payer policy activity
Pharmacy coverage policy for Bruton Tyrosine Kinase inhibitors intended to guide pharmacy prior-authorization and utilization management, including agent-specific criteria, dose and quantity limits, and initial/re-authorization durations.
Updated initial authorization duration for most BTK agents (Brukinsa, Calquence, Imbruvica, Jaypirca) from 3 months to 6 months and for Rhapsido and Wayrilz to 12 months.
Added a dose limitation for Brukinsa (zanubrutinib) limiting dosage to 320 mg daily.
Added coverage criteria for Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) with insufficient response to prior treatment.
Updated coverage criteria for Rhapsido (remibrutinib) based on phase 3 REMIX trials for chronic spontaneous urticaria (CSU).
Clarified that medications listed are subject to FDA dosage and administration prescribing information and that non-formulary exception authorizations may be approved up to 12 months.
Updated Jaypirca (pirtobrutinib) criteria for relapsed or refractory CLL/SLL removing the requirement of 2 prior lines of therapy including a BCL-2 inhibitor.
Updated Imbruvica (ibrutinib) coverage criteria to limit use to adults and adjusted chronic graft-versus-host disease age criteria to 1 year and older.
Added or updated dose/quantity limits: Brukinsa (zanubrutinib) dose limited to 320 mg daily and quantity limited to 60 tablets per 30 days; Wayrilz (rilzabrutinib) quantity limited to 60 tablets per 30 days; Imbruvica tablet/capsule/suspension quantity limits added.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.